$10.84
-0.93[-7.90%]
Last update: 2:53PM Get Real Time Here
Zentalis Pharma
(NASDAQ:ZNTL)Zentalis Pharma Stock (NASDAQ:ZNTL), Analyst Ratings, Price Targets, Predictions
Zentalis Pharmaceuticals Inc has a consensus price target of $41, established from looking at the 50 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., Wedbush, and Wedbush on February 28, 2024, February 28, 2024, and November 8, 2023. With an average price target of $24.33 between HC Wainwright & Co., Wedbush, and Wedbush, there's an implied 115.15% upside for Zentalis Pharmaceuticals Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Wedbush
Stifel
Morgan Stanley
Wells Fargo
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Zentalis Pharma
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 02/28/2024 | ZNTL | Buy Now | Zentalis Pharma | $11.31 | 306.72% | HC Wainwright & Co. | Andrew Fein | → $46 | Reiterates | Buy → Buy | Get Alert |
| 02/28/2024 | ZNTL | Buy Now | Zentalis Pharma | $11.31 | 32.63% | Wedbush | Robert Driscoll | $12 → $15 | Maintains | Neutral | Get Alert |
| 11/08/2023 | ZNTL | Buy Now | Zentalis Pharma | $11.31 | 6.1% | Wedbush | Robert Driscoll | $38 → $12 | Downgrade | Outperform → Neutral | Get Alert |
| 11/07/2023 | ZNTL | Buy Now | Zentalis Pharma | $11.31 | 218.3% | Stifel | Bradley Canino | $44 → $36 | Maintains | Buy | Get Alert |
| 11/07/2023 | ZNTL | Buy Now | Zentalis Pharma | $11.31 | 235.99% | Morgan Stanley | Matthew Harrison | $55 → $38 | Maintains | Overweight | Get Alert |
| 11/07/2023 | ZNTL | Buy Now | Zentalis Pharma | $11.31 | 306.72% | HC Wainwright & Co. | Andrew Fein | $55 → $46 | Maintains | Buy | Get Alert |
| 08/10/2023 | ZNTL | Buy Now | Zentalis Pharma | $11.31 | 342.09% | Wells Fargo | Derek Archila | $51 → $50 | Maintains | Overweight | Get Alert |
| 08/10/2023 | ZNTL | Buy Now | Zentalis Pharma | $11.31 | 235.99% | Wedbush | Robert Driscoll | → $38 | Reiterates | Outperform → Outperform | Get Alert |
| 08/10/2023 | ZNTL | Buy Now | Zentalis Pharma | $11.31 | 386.3% | HC Wainwright & Co. | Andrew Fein | → $55 | Reiterates | Buy → Buy | Get Alert |
| 06/07/2023 | ZNTL | Buy Now | Zentalis Pharma | $11.31 | 235.99% | Wedbush | Robert Driscoll | → $38 | Reiterates | Outperform → Outperform | Get Alert |
| 06/07/2023 | ZNTL | Buy Now | Zentalis Pharma | $11.31 | 342.09% | Stifel | Bradley Canino | $45 → $50 | Maintains | Buy | Get Alert |
| 06/02/2023 | ZNTL | Buy Now | Zentalis Pharma | $11.31 | 297.88% | Stifel | Bradley Canino | $45 → $45 | Maintains | Buy | Get Alert |
| 05/29/2023 | ZNTL | Buy Now | Zentalis Pharma | $11.31 | 297.88% | Stifel | Bradley Canino | $45 → $45 | Maintains | Buy | Get Alert |
| 05/26/2023 | ZNTL | Buy Now | Zentalis Pharma | $11.31 | 342.09% | Oppenheimer | Matthew Biegler | → $50 | Reiterates | Outperform → Outperform | Get Alert |
| 05/26/2023 | ZNTL | Buy Now | Zentalis Pharma | $11.31 | 235.99% | Wedbush | Robert Driscoll | $31 → $38 | Maintains | Outperform | Get Alert |
| 05/26/2023 | ZNTL | Buy Now | Zentalis Pharma | $11.31 | 386.3% | HC Wainwright & Co. | Andrew Fein | → $55 | Reiterates | Buy → Buy | Get Alert |
| 05/23/2023 | ZNTL | Buy Now | Zentalis Pharma | $11.31 | 297.88% | Stifel | Bradley Canino | $45 → $45 | Maintains | Buy | Get Alert |
| 05/19/2023 | ZNTL | Buy Now | Zentalis Pharma | $11.31 | 518.92% | Jefferies | Biren Amin | $120 → $70 | Maintains | Buy | Get Alert |
| 05/15/2023 | ZNTL | Buy Now | Zentalis Pharma | $11.31 | 297.88% | Stifel | Bradley Canino | $45 → $45 | Maintains | Buy | Get Alert |
FAQ
What is the target price for Zentalis Pharma (ZNTL)?
The latest price target for Zentalis Pharma (NASDAQ: ZNTL) was reported by HC Wainwright & Co. on February 28, 2024. The analyst firm set a price target for $46.00 expecting ZNTL to rise to within 12 months (a possible 324.35% upside). 22 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Zentalis Pharma (ZNTL)?
The latest analyst rating for Zentalis Pharma (NASDAQ: ZNTL) was provided by HC Wainwright & Co., and Zentalis Pharma reiterated their buy rating.
When was the last upgrade for Zentalis Pharma (ZNTL)?
There is no last upgrade for Zentalis Pharma.
When was the last downgrade for Zentalis Pharma (ZNTL)?
The last downgrade for Zentalis Pharmaceuticals Inc happened on November 8, 2023 when Wedbush changed their price target from $38 to $12 for Zentalis Pharmaceuticals Inc.
When is the next analyst rating going to be posted or updated for Zentalis Pharma (ZNTL)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Zentalis Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Zentalis Pharma was filed on February 28, 2024 so you should expect the next rating to be made available sometime around February 28, 2025.
Is the Analyst Rating Zentalis Pharma (ZNTL) correct?
While ratings are subjective and will change, the latest Zentalis Pharma (ZNTL) rating was a reiterated with a price target of $0.00 to $46.00. The current price Zentalis Pharma (ZNTL) is trading at is $10.84, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.